HUTCHMED (China) (HCM) reported $549M in revenue for fiscal 2025, −13.0% year on year. That ranks #2156 by revenue among 2853 SEC filers and #208 in Healthcare. Net income was $457M, a net margin of 83.3%. Revenue has grown 10.9% a year on average since 2016 ($216M then). The fiscal 2025 balance sheet shows $1.8B in total assets, $71.3M in cash and $68.2M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $549M | −13.0% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$39.2M | +$4.5M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $457M | +1,111.0% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$64.7M | −$65.2M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $14.1M | −21.1% | FY20252025-12-31 |
| Total assetsAssets | $1.8B | +37.6% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.2B | +62.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $71.3M | −53.7% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $68.2M | +14.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Profile
- Legal name
- HUTCHMED (China) Ltd
- Ticker
- HCM
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- CIK
- 0001648257
Filings
- 20-FMar 5, 2026Open filing →
- 20-FMar 19, 2025Open filing →
- 20-FFeb 28, 2024Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| AlvotechALVO | $586M | $27.9M |
| BioventusBVS | $568M | $22.7M |
| Organogenesis HoldingsORGO | $564M | $37.0M |
| HUTCHMED (China)HCM | $549M | $457M |
| AtricureATRC | $535M | −$11.4M |
| Mirum PharmaceuticalsMIRM | $521M | −$23.4M |
| VeracyteVCYT | $517M | $66.4M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=HUTCHMED (China) — Key figures |url=https://companiesranked.com/en/company/hutchmed-china |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). HUTCHMED (China) — Key figures. CompaniesRanked. https://companiesranked.com/en/company/hutchmed-chinaBibTeX
@misc{companiesranked-en-company-hutchmed-china-2026,
author = {{CompaniesRanked}},
title = {{HUTCHMED (China) — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/hutchmed-china}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001104659-26-023822 · March 5, 2026
{{cite web |title=HUTCHMED (China) — Key figures — 20-F (0001104659-26-023822) |url=https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-05}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.